SUSPENDED

Genetic Testing in Guiding Treatment for Patients With Brain Metastases

Conditions

CDK Gene Mutation Metastatic Malignant Neoplasm in the Brain Metastatic Malignant Solid Neoplasm NTRK Family Gene Mutation PI3K Gene Mutation ROS1 Gene Mutation KRAS G12C Mutation

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

This phase II trial studies how well genetic testing works in guiding treatment for patients with solid tumors that have spread to the brain. Several genes have been found to be altered or mutated in brain metastases such as NTRK, ROS1, CDK, PI3K, or KRAS G12C. Medications that target these genes such as abemaciclib, paxalisib, entrectinib and adagrasib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Genetic testing may help doctors tailor treatment for each mutation.

Official Title

Genomically-Guided Treatment Trial in Brain Metastases

Quick Facts

Study Start:2019-10-17

Study Completion:2028-06

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:SUSPENDED

Study ID

NCT03994796

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Participants must have histologically confirmed parenchymal metastatic disease to the brain from any solid tumor. Note: this includes patients that have controlled extracranial disease with progressive intracranial metastasis, as well as patients that have progressive intracranial and extracranial disease. * New or progressive brain metastases are defined as any one of the following: * Untreated measurable lesions in patients who have received surgery and/or stereotactic radiosurgery (SRS) to one or more other lesions. * Progressive measurable lesions after radiation, surgery, or prior systemic therapy * Residual or progressive lesions after surgery if asymptomatic. * Patients who have had prior whole-brain radiotherapy (WBRT) and/or SRS and then whose lesions have progressed by BM-RANO criteria or there are new lesions, are eligible. Lesions treated with SRS may be eligible if there is unequivocal evidence of progression. For patients with NTRK or ROS1 mutations, entrectinib may be used for newly diagnosed brain metastases. Similarly, for patients with KRAS G12C mutations, MRTX849 may be used for newly diagnosed brain metastases. * Patients who have not previously been treated with cranial radiation (e.g. WBRT or SRS) are eligible, but such patients must be asymptomatic or neurologically stable from their CNS metastases. * Measurable CNS disease (=\> 10 mm). * Ability to obtain magnetic resonance imaging (MRI)s with contrast * No surgery within 2 weeks prior to or after registration. * No chemotherapy within 14 days prior to registration (Note: for abemaciclib arm, a 21-day chemotherapy washout is required). * For melanoma, patients must have progressed after prior immune checkpoint blockade or for BRAF positive melanoma, BRAF/MEK inhibitors. * For lung cancer, EGFR mutant patients must have failed EGFR therapies * For HER2-positive breast cancer patients (regardless of ER/PR status), patients must have received at least one prior HER-2 directed therapy in the metastatic setting. * For triple negative breast cancer (TNBC), patients must have received at least one chemotherapy in the metastatic setting. * For estrogen receptor (ER) and/or progesterone receptor (PR)+ HER2-negative breast cancer, patients must have received at least one endocrine therapy in the metastatic setting. * Patients who have received prior treatment with any of the targeted treatments on this study are not eligible for that specific treatment arm(s), but could be eligible for other arms (e.g., a patient who has had prior treatment with abemaciclib would not be eligible for the abemaciclib arm, but could be eligible for another arm). * Presence of clinically actionable alteration in NTRK, ROS1, KRAS G12C or CDK pathway or PI3K pathway in both a brain metastasis and extracranial site per central review. * Not pregnant and not nursing, because this study involves investigational agents whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 14 days prior to registration is required (Note: for abemaciclib arm, pregnancy test is required =\< 7 days prior to registration). * No known current diffuse leptomeningeal involvement for the CDK, PI3K and NTRK arms (diffuse defined as leptomeningeal involvement throughout the CNS axis).Patients with focal leptomeningeal disease, with or without documented positive CSF cytology, are eligible. * Eastern Cooperative Oncology Group (ECOG) performance status 0-2. * Adequate organ function. * Absolute neutrophil count (ANC) \>= 1,500/mm\^3. * Platelet count \>= 100,000/mm\^3. * Total bilirubin =\< 1.5 x upper limit of normal (ULN) except in patients with Gilbert's disease. Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted. * Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN). * Creatinine =\< 1.5 mg/dL OR calculated (Calc.) creatinine clearance \> 45 mL/min except for patients in the adagrasib (MRTX849) (KRAS G12C) arm. For this arm, patients must have creatinine clearance ≥60 mL/min or glomerular filtration rate ≥60 mL/min/1.73m2 calculated using a validated prediction equation (e.g., Cockcroft-Gault, MDRD, or 24-hour urine CrCl). * No uncontrolled medical comorbidities per investigator discretion (e.g. interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea) * Radiation to symptomatic non-target sites within neural axis is allowed prior to registration without washout (provided there is at least one untreated target lesion for measurement on study and radiation is completed prior to registration). * Concurrent systemic corticosteroids are allowed if stable dose of dexamethasone for 7 days prior to registration. Baseline doses and changes in steroid dosing will be captured. * No concurrent administration of anticancer therapies (except for endocrine therapy or continuation of hormonal therapy or trastuzumab in breast cancer patients for the PI3K and CDK inhibitor arms). . No chemotherapy, targeted therapy or immunotherapy within 14 days prior to entering the study (Note: For abemaciclib arm, a 21-day chemotherapy washout is required). * Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug 14 days or 5 or more half-lives prior to registration on the study. * Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment. * Urine protein to creatinine (UPC) ratio \< 1 or urine protein =\< 1. * Recent acute myocardial infarction in the last 6 months or current angina pectoris are excluded. Patients with symptomatic bradycardia should have an electrocardiogram at baseline. If QT interval \> 470 msec, the patient is excluded. * Patients with uncontrolled type I or II diabetes mellitus should be excluded. Uncontrolled diabetes is defined as glycosylated hemoglobin (HbA1c) \> 9% in addition to fasting glucose \> 140 mg/dL on at least 2 occasions within 14 days prior to registration. * Hemoglobin \>= g/dL. Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion. * Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to registration. A washout period of at least 21 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy). * Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and registration. * Breast cancer patients who have received ribociclib or palbociclib are eligible as long as there is documentation of CDK4/6 pathway alteration on a biopsy or resection at the point of progression post-ribociclib or palbociclib. * For females of childbearing potential: A female of childbearing potential, must have a negative serum pregnancy test within 7 days prior to registration and agree to use a highly effective contraception method during the treatment period and for 3 weeks following the last dose of abemaciclib. Contraceptive methods may include an intrauterine device \[IUD\] or barrier method. If condoms are used as a barrier method, a spermicidal agent should be added as a double barrier protection. Cases of pregnancy that occur during maternal exposures to abemaciclib should be reported. If a patient or spouse/partner is determined to be pregnant following abemaciclib initiation, she must discontinue treatment immediately. Data on fetal outcome and breast-feeding are to be collected for regulatory reporting and drug safety evaluation. * Patients with active bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\] are excluded. Screening is not required for enrollment. * Patients with personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest, are excluded. * Hemoglobin ≥9.0 g/dL. Note: Transfusions will be allowed to achieve this provided the patient has not received more than 2 units of red blood cells in the prior 4 weeks. * Any of the following cardiovascular abnormalities within 6 months of study entry are excluded: symptomatic or uncontrolled atrial fibrillation, unstable angina pectoris or myocardial infarction, CHF ≥ NYHA Class 3, stroke or transient ischemic attack. * Ongoing need for medication known to cause prolonged QTc interval or that are substrates of CYP3A4 with narrow therapeutic index that cannot be switched to alternative treatment prior to study entry is excluded. * Prolonged QTc interval \>480 milliseconds or family history or medical history of Long QT syndrome is excluded.• * Known human immunodeficiency virus (HIV) infection or acute or chronic hepatitis B or C infection is excluded. Screening is not required for enrollment. Note that the following are permitted: * Patients treated for hepatitis C (HCV) with no detectable viral load; * Patients treated for HIV with no detectable viral load for at least 1 month prior to randomization while on a stable regimen of agents that are not strong inhibitors of CYP3A4; and * Patients with hepatitis B (HBV) receiving prophylaxis against reactivation of hepatitis B (either \[HBsAg-positive with normal ALT and HBV DNA \<2,000 IU/mL or \<10,000 copies/mL\] or \[HBsAg-negative and anti-HBc positive\]). * History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications is excluded. * Recovery from the adverse effects of prior therapy to baseline or Grade 1 (any grade alopecia and Grade ≤2 peripheral neuropathy are eligible). * For females of childbearing potential. It is not known whether MRTX849 presents a risk to the embryo or the fetus; however, based on the mechanism of action (KRAS G12C inhibition), effects on the reproductive system are not unexpected. MRTX849 is contraindicated in women who are pregnant or lactating. Women of childbearing potential and men receiving MRTX849 who are sexually active must employ an effective method of contraception throughout their period of treatment and for 6 months after their last treatment with MRTX849.	Pregnancy or breastfeeding Severe psychiatric disorders Active substance abuse Unstable medical conditions Inability to comply with study requirements

Inclusion Criteria

Exclusion Criteria

* Participants must have histologically confirmed parenchymal metastatic disease to the brain from any solid tumor. Note: this includes patients that have controlled extracranial disease with progressive intracranial metastasis, as well as patients that have progressive intracranial and extracranial disease.
* New or progressive brain metastases are defined as any one of the following:
* Untreated measurable lesions in patients who have received surgery and/or stereotactic radiosurgery (SRS) to one or more other lesions.
* Progressive measurable lesions after radiation, surgery, or prior systemic therapy
* Residual or progressive lesions after surgery if asymptomatic.
* Patients who have had prior whole-brain radiotherapy (WBRT) and/or SRS and then whose lesions have progressed by BM-RANO criteria or there are new lesions, are eligible. Lesions treated with SRS may be eligible if there is unequivocal evidence of progression. For patients with NTRK or ROS1 mutations, entrectinib may be used for newly diagnosed brain metastases. Similarly, for patients with KRAS G12C mutations, MRTX849 may be used for newly diagnosed brain metastases.
* Patients who have not previously been treated with cranial radiation (e.g. WBRT or SRS) are eligible, but such patients must be asymptomatic or neurologically stable from their CNS metastases.
* Measurable CNS disease (=\> 10 mm).
* Ability to obtain magnetic resonance imaging (MRI)s with contrast
* No surgery within 2 weeks prior to or after registration.
* No chemotherapy within 14 days prior to registration (Note: for abemaciclib arm, a 21-day chemotherapy washout is required).
* For melanoma, patients must have progressed after prior immune checkpoint blockade or for BRAF positive melanoma, BRAF/MEK inhibitors.
* For lung cancer, EGFR mutant patients must have failed EGFR therapies
* For HER2-positive breast cancer patients (regardless of ER/PR status), patients must have received at least one prior HER-2 directed therapy in the metastatic setting.
* For triple negative breast cancer (TNBC), patients must have received at least one chemotherapy in the metastatic setting.
* For estrogen receptor (ER) and/or progesterone receptor (PR)+ HER2-negative breast cancer, patients must have received at least one endocrine therapy in the metastatic setting.
* Patients who have received prior treatment with any of the targeted treatments on this study are not eligible for that specific treatment arm(s), but could be eligible for other arms (e.g., a patient who has had prior treatment with abemaciclib would not be eligible for the abemaciclib arm, but could be eligible for another arm).
* Presence of clinically actionable alteration in NTRK, ROS1, KRAS G12C or CDK pathway or PI3K pathway in both a brain metastasis and extracranial site per central review.
* Not pregnant and not nursing, because this study involves investigational agents whose genotoxic, mutagenic and teratogenic effects on the developing fetus and newborn are unknown. Therefore, for women of childbearing potential only, a negative pregnancy test done =\< 14 days prior to registration is required (Note: for abemaciclib arm, pregnancy test is required =\< 7 days prior to registration).
* No known current diffuse leptomeningeal involvement for the CDK, PI3K and NTRK arms (diffuse defined as leptomeningeal involvement throughout the CNS axis).Patients with focal leptomeningeal disease, with or without documented positive CSF cytology, are eligible.
* Eastern Cooperative Oncology Group (ECOG) performance status 0-2.
* Adequate organ function.
* Absolute neutrophil count (ANC) \>= 1,500/mm\^3.
* Platelet count \>= 100,000/mm\^3.
* Total bilirubin =\< 1.5 x upper limit of normal (ULN) except in patients with Gilbert's disease. Patients with Gilbert's syndrome with a total bilirubin ≤2.0 times ULN and direct bilirubin within normal limits are permitted.
* Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) =\< 2.5 x upper limit of normal (ULN).
* Creatinine =\< 1.5 mg/dL OR calculated (Calc.) creatinine clearance \> 45 mL/min except for patients in the adagrasib (MRTX849) (KRAS G12C) arm. For this arm, patients must have creatinine clearance ≥60 mL/min or glomerular filtration rate ≥60 mL/min/1.73m2 calculated using a validated prediction equation (e.g., Cockcroft-Gault, MDRD, or 24-hour urine CrCl).
* No uncontrolled medical comorbidities per investigator discretion (e.g. interstitial lung disease, severe dyspnea at rest or requiring oxygen therapy, severe renal impairment \[e.g. estimated creatinine clearance \<30ml/min\], history of major surgical resection involving the stomach or small bowel, or preexisting Crohn's disease or ulcerative colitis or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea)
* Radiation to symptomatic non-target sites within neural axis is allowed prior to registration without washout (provided there is at least one untreated target lesion for measurement on study and radiation is completed prior to registration).
* Concurrent systemic corticosteroids are allowed if stable dose of dexamethasone for 7 days prior to registration. Baseline doses and changes in steroid dosing will be captured.
* No concurrent administration of anticancer therapies (except for endocrine therapy or continuation of hormonal therapy or trastuzumab in breast cancer patients for the PI3K and CDK inhibitor arms). . No chemotherapy, targeted therapy or immunotherapy within 14 days prior to entering the study (Note: For abemaciclib arm, a 21-day chemotherapy washout is required).
* Chronic concomitant treatment with strong inhibitors of CYP3A4 is not allowed on this study. Patients on strong CYP3A4 inhibitors must discontinue the drug 14 days or 5 or more half-lives prior to registration on the study.
* Chronic concomitant treatment with strong CYP3A4 inducers is not allowed. Patients must discontinue the drug 14 days prior to the start of study treatment.
* Urine protein to creatinine (UPC) ratio \< 1 or urine protein =\< 1.
* Recent acute myocardial infarction in the last 6 months or current angina pectoris are excluded. Patients with symptomatic bradycardia should have an electrocardiogram at baseline. If QT interval \> 470 msec, the patient is excluded.
* Patients with uncontrolled type I or II diabetes mellitus should be excluded. Uncontrolled diabetes is defined as glycosylated hemoglobin (HbA1c) \> 9% in addition to fasting glucose \> 140 mg/dL on at least 2 occasions within 14 days prior to registration.
* Hemoglobin \>= g/dL. Patients may receive erythrocyte transfusions to achieve this hemoglobin level at the discretion of the investigator. Initial treatment must not begin earlier than the day after the erythrocyte transfusion.
* Patients who received chemotherapy must have recovered (Common Terminology Criteria for Adverse Events \[CTCAE\] Grade ≤1) from the acute effects of chemotherapy except for residual alopecia or Grade 2 peripheral neuropathy prior to registration. A washout period of at least 21 days is required between last chemotherapy dose and registration (provided the patient did not receive radiotherapy).
* Patients who received adjuvant radiotherapy must have completed and fully recovered from the acute effects of radiotherapy. A washout period of at least 14 days is required between end of radiotherapy and registration.
* Breast cancer patients who have received ribociclib or palbociclib are eligible as long as there is documentation of CDK4/6 pathway alteration on a biopsy or resection at the point of progression post-ribociclib or palbociclib.
* For females of childbearing potential: A female of childbearing potential, must have a negative serum pregnancy test within 7 days prior to registration and agree to use a highly effective contraception method during the treatment period and for 3 weeks following the last dose of abemaciclib. Contraceptive methods may include an intrauterine device \[IUD\] or barrier method. If condoms are used as a barrier method, a spermicidal agent should be added as a double barrier protection. Cases of pregnancy that occur during maternal exposures to abemaciclib should be reported. If a patient or spouse/partner is determined to be pregnant following abemaciclib initiation, she must discontinue treatment immediately. Data on fetal outcome and breast-feeding are to be collected for regulatory reporting and drug safety evaluation.
* Patients with active bacterial infection (requiring intravenous \[IV\] antibiotics at time of initiating study treatment), fungal infection, or detectable viral infection (such as known human immunodeficiency virus positivity or with known active hepatitis B or C \[for example, hepatitis B surface antigen positive\] are excluded. Screening is not required for enrollment.
* Patients with personal history of any of the following conditions: syncope of cardiovascular etiology, ventricular arrhythmia of pathological origin (including, but not limited to, ventricular tachycardia and ventricular fibrillation), or sudden cardiac arrest, are excluded.
* Hemoglobin ≥9.0 g/dL. Note: Transfusions will be allowed to achieve this provided the patient has not received more than 2 units of red blood cells in the prior 4 weeks.
* Any of the following cardiovascular abnormalities within 6 months of study entry are excluded: symptomatic or uncontrolled atrial fibrillation, unstable angina pectoris or myocardial infarction, CHF ≥ NYHA Class 3, stroke or transient ischemic attack.
* Ongoing need for medication known to cause prolonged QTc interval or that are substrates of CYP3A4 with narrow therapeutic index that cannot be switched to alternative treatment prior to study entry is excluded.
* Prolonged QTc interval \>480 milliseconds or family history or medical history of Long QT syndrome is excluded.•
* Known human immunodeficiency virus (HIV) infection or acute or chronic hepatitis B or C infection is excluded. Screening is not required for enrollment. Note that the following are permitted:
* Patients treated for hepatitis C (HCV) with no detectable viral load;
* Patients treated for HIV with no detectable viral load for at least 1 month prior to randomization while on a stable regimen of agents that are not strong inhibitors of CYP3A4; and
* Patients with hepatitis B (HBV) receiving prophylaxis against reactivation of hepatitis B (either \[HBsAg-positive with normal ALT and HBV DNA \<2,000 IU/mL or \<10,000 copies/mL\] or \[HBsAg-negative and anti-HBc positive\]).
* History of intestinal disease or major gastric surgery likely to alter absorption of study treatment or inability to swallow oral medications is excluded.
* Recovery from the adverse effects of prior therapy to baseline or Grade 1 (any grade alopecia and Grade ≤2 peripheral neuropathy are eligible).
* For females of childbearing potential. It is not known whether MRTX849 presents a risk to the embryo or the fetus; however, based on the mechanism of action (KRAS G12C inhibition), effects on the reproductive system are not unexpected. MRTX849 is contraindicated in women who are pregnant or lactating. Women of childbearing potential and men receiving MRTX849 who are sexually active must employ an effective method of contraception throughout their period of treatment and for 6 months after their last treatment with MRTX849.

Pregnancy or breastfeeding
Severe psychiatric disorders
Active substance abuse
Unstable medical conditions
Inability to comply with study requirements

Contacts and Locations

Principal Investigator

Priscilla Brastianos, MD

STUDY_CHAIR

Massachusetts General Hospital

Study Locations (Sites)

Anchorage Associates in Radiation Medicine

Anchorage, Alaska, 98508

United States

Anchorage Radiation Therapy Center

Anchorage, Alaska, 99504

United States

Alaska Breast Care and Surgery LLC

Anchorage, Alaska, 99508

United States

Alaska Oncology and Hematology LLC

Anchorage, Alaska, 99508

United States

Alaska Women's Cancer Care

Anchorage, Alaska, 99508

United States

Anchorage Oncology Centre

Anchorage, Alaska, 99508

United States

Katmai Oncology Group

Anchorage, Alaska, 99508

United States

Providence Alaska Medical Center

Anchorage, Alaska, 99508

United States

Cancer Center at Saint Joseph's

Phoenix, Arizona, 85004

United States

Mayo Clinic Hospital in Arizona

Phoenix, Arizona, 85054

United States

Mercy Hospital Fort Smith

Fort Smith, Arkansas, 72903

United States

CHI Saint Vincent Cancer Center Hot Springs

Hot Springs, Arkansas, 71913

United States

Mission Hope Medical Oncology - Arroyo Grande

Arroyo Grande, California, 93420

United States

Providence Saint Joseph Medical Center/Disney Family Cancer Center

Burbank, California, 91505

United States

Epic Care-Dublin

Dublin, California, 94568

United States

Bay Area Breast Surgeons Inc

Emeryville, California, 94608

United States

Epic Care Partners in Cancer Care

Emeryville, California, 94608

United States

UC San Diego Moores Cancer Center

La Jolla, California, 92093

United States

Cedars Sinai Medical Center

Los Angeles, California, 90048

United States

Contra Costa Regional Medical Center

Martinez, California, 94553-3156

United States

Alta Bates Summit Medical Center - Summit Campus

Oakland, California, 94609

United States

Bay Area Tumor Institute

Oakland, California, 94609

United States

UC Irvine Health/Chao Family Comprehensive Cancer Center

Orange, California, 92868

United States

Sharp Memorial Hospital

San Diego, California, 92123

United States

Pacific Central Coast Health Center-San Luis Obispo

San Luis Obispo, California, 93401

United States

Mission Hope Medical Oncology - Santa Maria

Santa Maria, California, 93444

United States

Torrance Memorial Physician Network - Cancer Care

Torrance, California, 90505

United States

Torrance Memorial Medical Center

Torrance, California, 90509

United States

Epic Care Cyberknife Center

Walnut Creek, California, 94597

United States

Penrose-Saint Francis Healthcare

Colorado Springs, Colorado, 80907

United States

Rocky Mountain Cancer Centers-Penrose

Colorado Springs, Colorado, 80907

United States

AdventHealth Porter

Denver, Colorado, 80210

United States

CommonSpirit Cancer Center Mercy

Durango, Colorado, 81301

United States

Mercy Medical Center

Durango, Colorado, 81301

United States

Saint Anthony Hospital

Lakewood, Colorado, 80228

United States

AdventHealth Littleton

Littleton, Colorado, 80122

United States

Longmont United Hospital

Longmont, Colorado, 80501

United States

Rocky Mountain Cancer Centers-Longmont

Longmont, Colorado, 80501

United States

AdventHealth Parker

Parker, Colorado, 80138

United States

Saint Mary Corwin Medical Center

Pueblo, Colorado, 81004

United States

Smilow Cancer Center/Yale-New Haven Hospital

New Haven, Connecticut, 06510

United States

Yale University

New Haven, Connecticut, 06520

United States

Boca Raton Regional Hospital

Boca Raton, Florida, 33486

United States

UM Sylvester Comprehensive Cancer Center at Coral Gables

Coral Gables, Florida, 33146

United States

UM Sylvester Comprehensive Cancer Center at Deerfield Beach

Deerfield Beach, Florida, 33442

United States

Holy Cross Hospital

Fort Lauderdale, Florida, 33308

United States

Mayo Clinic in Florida

Jacksonville, Florida, 32224-9980

United States

University of Miami Miller School of Medicine-Sylvester Cancer Center

Miami, Florida, 33136

United States

Emory University Hospital Midtown

Atlanta, Georgia, 30308

United States

Emory University Hospital/Winship Cancer Institute

Atlanta, Georgia, 30322

United States

Emory Saint Joseph's Hospital

Atlanta, Georgia, 30342

United States

Saint Alphonsus Cancer Care Center-Boise

Boise, Idaho, 83706

United States

Saint Luke's Cancer Institute - Boise

Boise, Idaho, 83712

United States

Saint Alphonsus Cancer Care Center-Caldwell

Caldwell, Idaho, 83605

United States

Kootenai Health - Coeur d'Alene

Coeur d'Alene, Idaho, 83814

United States

Walter Knox Memorial Hospital

Emmett, Idaho, 83617

United States

Saint Luke's Cancer Institute - Fruitland

Fruitland, Idaho, 83619

United States

Idaho Urologic Institute-Meridian

Meridian, Idaho, 83642

United States

Saint Luke's Cancer Institute - Meridian

Meridian, Idaho, 83642

United States

Saint Alphonsus Cancer Care Center-Nampa

Nampa, Idaho, 83687

United States

Saint Luke's Cancer Institute - Nampa

Nampa, Idaho, 83687

United States

Kootenai Clinic Cancer Services - Post Falls

Post Falls, Idaho, 83854

United States

Kootenai Clinic Cancer Services - Sandpoint

Sandpoint, Idaho, 83864

United States

Saint Luke's Cancer Institute - Twin Falls

Twin Falls, Idaho, 83301

United States

OSF Saint Anthony's Health Center

Alton, Illinois, 62002

United States

Rush-Copley Medical Center

Aurora, Illinois, 60504

United States

Advocate Good Shepherd Hospital

Barrington, Illinois, 60010

United States

Northwestern University

Chicago, Illinois, 60611

United States

Rush University Medical Center

Chicago, Illinois, 60612

United States

University of Illinois

Chicago, Illinois, 60612

United States

University of Chicago Comprehensive Cancer Center

Chicago, Illinois, 60637

United States

Advocate Illinois Masonic Medical Center

Chicago, Illinois, 60657

United States

AMG Crystal Lake - Oncology

Crystal Lake, Illinois, 60014

United States

Carle at The Riverfront

Danville, Illinois, 61832

United States

Northwestern Medicine Cancer Center Kishwaukee

DeKalb, Illinois, 60115

United States

Advocate Good Samaritan Hospital

Downers Grove, Illinois, 60515

United States

Carle Physician Group-Effingham

Effingham, Illinois, 62401

United States

Advocate Sherman Hospital

Elgin, Illinois, 60123

United States

Northwestern Medicine Cancer Center Delnor

Geneva, Illinois, 60134

United States

Advocate South Suburban Hospital

Hazel Crest, Illinois, 60429

United States

Northwestern Medicine Lake Forest Hospital

Lake Forest, Illinois, 60045

United States

Carle Physician Group-Mattoon/Charleston

Mattoon, Illinois, 61938

United States

SSM Health Good Samaritan

Mount Vernon, Illinois, 62864

United States

Advocate Christ Medical Center

Oak Lawn, Illinois, 60453-2699

United States

Advocate Lutheran General Hospital

Park Ridge, Illinois, 60068

United States

Carle Cancer Center

Urbana, Illinois, 61801

United States

The Carle Foundation Hospital

Urbana, Illinois, 61801

United States

Northwestern Medicine Cancer Center Warrenville

Warrenville, Illinois, 60555

United States

Rush-Copley Healthcare Center

Yorkville, Illinois, 60560

United States

Mary Greeley Medical Center

Ames, Iowa, 50010

United States

McFarland Clinic - Ames

Ames, Iowa, 50010

United States

UI Health Care Mission Cancer and Blood - Ankeny Clinic

Ankeny, Iowa, 50023

United States

McFarland Clinic - Boone

Boone, Iowa, 50036

United States

Saint Anthony Regional Hospital

Carroll, Iowa, 51401

United States

Mercy Cancer Center-West Lakes

Clive, Iowa, 50325

United States

UI Health Care Mission Cancer and Blood - West Des Moines Clinic

Clive, Iowa, 50325

United States

Alegent Health Mercy Hospital

Council Bluffs, Iowa, 51503

United States

Greater Regional Medical Center

Creston, Iowa, 50801

United States

Iowa Methodist Medical Center

Des Moines, Iowa, 50309

United States

UI Health Care Mission Cancer and Blood - Des Moines Clinic

Des Moines, Iowa, 50309

United States

Broadlawns Medical Center

Des Moines, Iowa, 50314

United States

Mercy Medical Center - Des Moines

Des Moines, Iowa, 50314

United States

UI Health Care Mission Cancer and Blood - Laurel Clinic

Des Moines, Iowa, 50314

United States

Iowa Lutheran Hospital

Des Moines, Iowa, 50316

United States

McFarland Clinic - Trinity Cancer Center

Fort Dodge, Iowa, 50501

United States

UI Healthcare Mission Cancer and Blood - Fort Dodge

Fort Dodge, Iowa, 50501

United States

University of Iowa/Holden Comprehensive Cancer Center

Iowa City, Iowa, 52242

United States

McFarland Clinic - Jefferson

Jefferson, Iowa, 50129

United States

McFarland Clinic - Marshalltown

Marshalltown, Iowa, 50158

United States

UI Health Care Mission Cancer and Blood - Waukee Clinic

Waukee, Iowa, 50263

United States

Methodist West Hospital

West Des Moines, Iowa, 50266-7700

United States

Mercy Medical Center-West Lakes

West Des Moines, Iowa, 50266

United States

Central Care Cancer Center - Garden City

Garden City, Kansas, 67846

United States

Central Care Cancer Center - Great Bend

Great Bend, Kansas, 67530

United States

HaysMed

Hays, Kansas, 67601

United States

University of Kansas Cancer Center

Kansas City, Kansas, 66160

United States

Lawrence Memorial Hospital

Lawrence, Kansas, 66044

United States

The University of Kansas Cancer Center - Olathe

Olathe, Kansas, 66061

United States

University of Kansas Cancer Center-Overland Park

Overland Park, Kansas, 66210

United States

University of Kansas Hospital-Indian Creek Campus

Overland Park, Kansas, 66211

United States

University of Kansas Hospital-Westwood Cancer Center

Westwood, Kansas, 66205

United States

Flaget Memorial Hospital

Bardstown, Kentucky, 40004

United States

Commonwealth Cancer Center-Corbin

Corbin, Kentucky, 40701

United States

Saint Joseph Radiation Oncology Resource Center

Lexington, Kentucky, 40504

United States

Saint Joseph Hospital East

Lexington, Kentucky, 40509

United States

University of Kentucky/Markey Cancer Center

Lexington, Kentucky, 40536

United States

Saint Joseph London

London, Kentucky, 40741

United States

Jewish Hospital

Louisville, Kentucky, 40202

United States

Saints Mary and Elizabeth Hospital

Louisville, Kentucky, 40215

United States

UofL Health Medical Center Northeast

Louisville, Kentucky, 40245

United States

Jewish Hospital Medical Center South

Shepherdsville, Kentucky, 40165

United States

Ochsner LSU Health Monroe Medical Center

Monroe, Louisiana, 71202

United States

Louisiana State University Health Science Center

New Orleans, Louisiana, 70112

United States

Tulane University School of Medicine

New Orleans, Louisiana, 70112

United States

University Medical Center New Orleans

New Orleans, Louisiana, 70112

United States

Ochsner LSU Health Saint Mary's Medical Center

Shreveport, Louisiana, 71101

United States

LSU Health Sciences Center at Shreveport

Shreveport, Louisiana, 71103

United States

Massachusetts General Hospital Cancer Center

Boston, Massachusetts, 02114

United States

Dana-Farber Cancer Institute

Boston, Massachusetts, 02215

United States

Mercy Medical Center

Springfield, Massachusetts, 01104

United States

UMass Memorial Medical Center - University Campus

Worcester, Massachusetts, 01655

United States

Hickman Cancer Center

Adrian, Michigan, 49221

United States

Trinity Health Saint Joseph Mercy Hospital Ann Arbor

Ann Arbor, Michigan, 48106

United States

University of Michigan Comprehensive Cancer Center

Ann Arbor, Michigan, 48109

United States

Bronson Battle Creek

Battle Creek, Michigan, 49017

United States

Trinity Health IHA Medical Group Hematology Oncology - Brighton

Brighton, Michigan, 48114

United States

Trinity Health Medical Center - Brighton

Brighton, Michigan, 48114

United States

University of Michigan - Brighton Center for Specialty Care

Brighton, Michigan, 48116

United States

Henry Ford Cancer Institute-Downriver

Brownstown, Michigan, 48183

United States

Trinity Health IHA Medical Group Hematology Oncology - Canton

Canton, Michigan, 48188

United States

Trinity Health Medical Center - Canton

Canton, Michigan, 48188

United States

Caro Cancer Center

Caro, Michigan, 48723

United States

Chelsea Hospital

Chelsea, Michigan, 48118

United States

Trinity Health IHA Medical Group Hematology Oncology - Chelsea Hospital

Chelsea, Michigan, 48118

United States

Hematology Oncology Consultants-Clarkston

Clarkston, Michigan, 48346

United States

Newland Medical Associates-Clarkston

Clarkston, Michigan, 48346

United States

Henry Ford Macomb Hospital-Clinton Township

Clinton Township, Michigan, 48038

United States

Henry Ford Medical Center-Fairlane

Dearborn, Michigan, 48126

United States

Henry Ford Hospital

Detroit, Michigan, 48202

United States

Henry Ford Health Saint John Hospital

Detroit, Michigan, 48236

United States

Henry Ford River District Hospital

East China Township, Michigan, 48054

United States

Cancer Hematology Centers - Flint

Flint, Michigan, 48503

United States

Genesee Hematology Oncology PC

Flint, Michigan, 48503

United States

Genesys Hurley Cancer Institute

Flint, Michigan, 48503

United States

Hurley Medical Center

Flint, Michigan, 48503

United States

Corewell Health Grand Rapids Hospitals - Butterworth Hospital

Grand Rapids, Michigan, 49503

United States

Corewell Health Grand Rapids Hospitals - Helen DeVos Children's Hospital

Grand Rapids, Michigan, 49503

United States

Trinity Health Grand Rapids Hospital

Grand Rapids, Michigan, 49503

United States

Henry Ford Saint John Hospital - Academic

Grosse Pointe Woods, Michigan, 48236

United States

Henry Ford Saint John Hospital - Breast

Grosse Pointe Woods, Michigan, 48236

United States

Henry Ford Saint John Hospital - Van Elslander

Grosse Pointe Woods, Michigan, 48236

United States

Allegiance Health

Jackson, Michigan, 49201

United States

Bronson Methodist Hospital

Kalamazoo, Michigan, 49007

United States

West Michigan Cancer Center

Kalamazoo, Michigan, 49007

United States

Beacon Kalamazoo Cancer Center

Kalamazoo, Michigan, 49009

United States

Beacon Kalamazoo

Kalamazoo, Michigan, 49048

United States

University of Michigan Health - Sparrow Lansing

Lansing, Michigan, 48912

United States

Hope Cancer Clinic

Livonia, Michigan, 48154

United States

Trinity Health Saint Mary Mercy Livonia Hospital

Livonia, Michigan, 48154

United States

Henry Ford Saint John Hospital - Macomb Medical

Macomb, Michigan, 48044

United States

Henry Ford Warren Hospital - Breast Macomb

Macomb, Michigan, 48044

United States

Saint Mary's Oncology/Hematology Associates of Marlette

Marlette, Michigan, 48453

United States

Toledo Clinic Cancer Centers-Monroe

Monroe, Michigan, 48162

United States

Trinity Health Muskegon Hospital

Muskegon, Michigan, 49444

United States

Corewell Health Lakeland Hospitals - Niles Hospital

Niles, Michigan, 49120

United States

Cancer and Hematology Centers of Western Michigan - Norton Shores

Norton Shores, Michigan, 49444

United States

Henry Ford Health Providence Novi Hospital

Novi, Michigan, 48374

United States

Henry Ford Medical Center-Columbus

Novi, Michigan, 48377

United States

Hope Cancer Center

Pontiac, Michigan, 48341

United States

Michigan Healthcare Professionals Pontiac

Pontiac, Michigan, 48341

United States

Newland Medical Associates-Pontiac

Pontiac, Michigan, 48341

United States

Trinity Health Saint Joseph Mercy Oakland Hospital

Pontiac, Michigan, 48341

United States

Corewell Health Reed City Hospital

Reed City, Michigan, 49677

United States

Henry Ford Rochester Hospital

Rochester Hills, Michigan, 48309

United States

MyMichigan Medical Center Saginaw

Saginaw, Michigan, 48601

United States

Oncology Hematology Associates of Saginaw Valley PC

Saginaw, Michigan, 48604

United States

Corewell Health Lakeland Hospitals - Marie Yeager Cancer Center

Saint Joseph, Michigan, 49085

United States

Corewell Health Lakeland Hospitals - Saint Joseph Hospital

Saint Joseph, Michigan, 49085

United States

Henry Ford Macomb Health Center - Shelby Township

Shelby, Michigan, 48315

United States

Henry Ford Health Providence Southfield Hospital

Southfield, Michigan, 48075

United States

Bhadresh Nayak MD PC-Sterling Heights

Sterling Heights, Michigan, 48312

United States

MyMichigan Medical Center Tawas

Tawas City, Michigan, 48764

United States

Munson Medical Center

Traverse City, Michigan, 49684

United States

Advanced Breast Care Center PLLC

Warren, Michigan, 48088

United States

Henry Ford Health Warren Hospital

Warren, Michigan, 48093

United States

Henry Ford Madison Heights Hospital - Breast

Warren, Michigan, 48093

United States

Henry Ford Warren Hospital - GLCMS

Warren, Michigan, 48093

United States

Macomb Hematology Oncology PC

Warren, Michigan, 48093

United States

Henry Ford West Bloomfield Hospital

West Bloomfield, Michigan, 48322

United States

Saint Mary's Oncology/Hematology Associates of West Branch

West Branch, Michigan, 48661

United States

University of Michigan Health - West

Wyoming, Michigan, 49519

United States

Huron Gastroenterology PC

Ypsilanti, Michigan, 48106

United States

Trinity Health IHA Medical Group Hematology Oncology Ann Arbor Campus

Ypsilanti, Michigan, 48197

United States

Fairview Ridges Hospital

Burnsville, Minnesota, 55337

United States

Minnesota Oncology - Burnsville

Burnsville, Minnesota, 55337

United States

Cambridge Medical Center

Cambridge, Minnesota, 55008

United States

Mercy Hospital

Coon Rapids, Minnesota, 55433

United States

Fairview Southdale Hospital

Edina, Minnesota, 55435

United States

Unity Hospital

Fridley, Minnesota, 55432

United States

Fairview Clinics and Surgery Center Maple Grove

Maple Grove, Minnesota, 55369

United States

Minnesota Oncology Hematology PA-Maplewood

Maplewood, Minnesota, 55109

United States

Saint John's Hospital - Healtheast

Maplewood, Minnesota, 55109

United States

Abbott-Northwestern Hospital

Minneapolis, Minnesota, 55407

United States

Hennepin County Medical Center

Minneapolis, Minnesota, 55415

United States

Health Partners Inc

Minneapolis, Minnesota, 55454

United States

Monticello Cancer Center

Monticello, Minnesota, 55362

United States

New Ulm Medical Center

New Ulm, Minnesota, 56073

United States

Fairview Northland Medical Center

Princeton, Minnesota, 55371

United States

North Memorial Medical Health Center

Robbinsdale, Minnesota, 55422

United States

Mayo Clinic in Rochester

Rochester, Minnesota, 55905

United States

Coborn Cancer Center at Saint Cloud Hospital

Saint Cloud, Minnesota, 56303

United States

Park Nicollet Clinic - Saint Louis Park

Saint Louis Park, Minnesota, 55416

United States

Regions Hospital

Saint Paul, Minnesota, 55101

United States

United Hospital

Saint Paul, Minnesota, 55102

United States

Saint Francis Regional Medical Center

Shakopee, Minnesota, 55379

United States

Lakeview Hospital

Stillwater, Minnesota, 55082

United States

Ridgeview Medical Center

Waconia, Minnesota, 55387

United States

Rice Memorial Hospital

Willmar, Minnesota, 56201

United States

Minnesota Oncology Hematology PA-Woodbury

Woodbury, Minnesota, 55125

United States

Fairview Lakes Medical Center

Wyoming, Minnesota, 55092

United States

University of Mississippi Medical Center

Jackson, Mississippi, 39216

United States

Mercy Oncology and Hematology - Clayton-Clarkson

Ballwin, Missouri, 63011

United States

Central Care Cancer Center - Bolivar

Bolivar, Missouri, 65613

United States

Cox Cancer Center Branson

Branson, Missouri, 65616

United States

Siteman Cancer Center at Saint Peters Hospital

City of Saint Peters, Missouri, 63376

United States

MU Health - University Hospital/Ellis Fischel Cancer Center

Columbia, Missouri, 65212

United States

Siteman Cancer Center at West County Hospital

Creve Coeur, Missouri, 63141

United States

Freeman Health System

Joplin, Missouri, 64804

United States

Mercy Hospital Joplin

Joplin, Missouri, 64804

United States

University of Kansas Cancer Center - North

Kansas City, Missouri, 64154

United States

University of Kansas Cancer Center - Lee's Summit

Lee's Summit, Missouri, 64064

United States

University of Kansas Cancer Center at North Kansas City Hospital

North Kansas City, Missouri, 64116

United States

Mercy Clinic-Rolla-Cancer and Hematology

Rolla, Missouri, 65401

United States

Phelps Health Delbert Day Cancer Institute

Rolla, Missouri, 65401

United States

Heartland Regional Medical Center

Saint Joseph, Missouri, 64506

United States

Mercy Hospital Springfield

Springfield, Missouri, 65804

United States

CoxHealth South Hospital

Springfield, Missouri, 65807

United States

Mercy Infusion Center - Chippewa

St Louis, Missouri, 63109

United States

Washington University School of Medicine

St Louis, Missouri, 63110

United States

Mercy Hospital South

St Louis, Missouri, 63128

United States

Siteman Cancer Center-South County

St Louis, Missouri, 63129

United States

Siteman Cancer Center at Christian Hospital

St Louis, Missouri, 63136

United States

Mercy Hospital Saint Louis

St Louis, Missouri, 63141

United States

Mercy Hospital Washington

Washington, Missouri, 63090

United States

Community Hospital of Anaconda

Anaconda, Montana, 59711

United States

Billings Clinic Cancer Center

Billings, Montana, 59101

United States

Bozeman Health Deaconess Hospital

Bozeman, Montana, 59715

United States

Benefis Sletten Cancer Institute

Great Falls, Montana, 59405

United States

Great Falls Clinic

Great Falls, Montana, 59405

United States

Logan Health Medical Center

Kalispell, Montana, 59901

United States

Saint Patrick Hospital - Community Hospital

Missoula, Montana, 59802

United States

Community Medical Center

Missoula, Montana, 59804

United States

Nebraska Cancer Specialists/Oncology Hematology West PC

Grand Island, Nebraska, 68803

United States

CHI Health Good Samaritan

Kearney, Nebraska, 68847

United States

Saint Elizabeth Regional Medical Center

Lincoln, Nebraska, 68510

United States

Alegent Health Immanuel Medical Center

Omaha, Nebraska, 68122

United States

Alegent Health Bergan Mercy Medical Center

Omaha, Nebraska, 68124

United States

Alegent Health Lakeside Hospital

Omaha, Nebraska, 68130

United States

Creighton University Medical Center

Omaha, Nebraska, 68131

United States

Midlands Community Hospital

Papillion, Nebraska, 68046

United States

Dartmouth Hitchcock Medical Center/Dartmouth Cancer Center

Lebanon, New Hampshire, 03756

United States

Morristown Medical Center

Morristown, New Jersey, 07960

United States

Jersey Shore Medical Center

Neptune City, New Jersey, 07753

United States

Capital Health Medical Center-Hopewell

Pennington, New Jersey, 08534

United States

Overlook Hospital

Summit, New Jersey, 07902

United States

Lovelace Medical Center-Saint Joseph Square

Albuquerque, New Mexico, 87102

United States

University of New Mexico Cancer Center

Albuquerque, New Mexico, 87106

United States

Lovelace Radiation Oncology

Albuquerque, New Mexico, 87109

United States

New York-Presbyterian/Brooklyn Methodist Hospital

Brooklyn, New York, 11215

United States

Arnot Ogden Medical Center/Falck Cancer Center

Elmira, New York, 14905

United States

Glens Falls Hospital

Glens Falls, New York, 12801

United States

Northwell Health/Center for Advanced Medicine

Lake Success, New York, 11042

United States

Laura and Isaac Perlmutter Cancer Center at NYU Langone

New York, New York, 10016

United States

Manhattan Eye Ear and Throat Hospital

New York, New York, 10065

United States

NYP/Weill Cornell Medical Center

New York, New York, 10065

United States

Lenox Hill Hospital

New York, New York, 10075

United States

University of Rochester

Rochester, New York, 14642

United States

State University of New York Upstate Medical University

Syracuse, New York, 13210

United States

Upstate Cancer Center at Verona

Verona, New York, 13478

United States

UNC Lineberger Comprehensive Cancer Center

Chapel Hill, North Carolina, 27599

United States

Carolinas Medical Center/Levine Cancer Institute

Charlotte, North Carolina, 28203

United States

Atrium Health Pineville/LCI-Pineville

Charlotte, North Carolina, 28210

United States

Atrium Health Cabarrus/LCI-Concord

Concord, North Carolina, 28025

United States

Duke University Medical Center

Durham, North Carolina, 27710

United States

Margaret R Pardee Memorial Hospital

Hendersonville, North Carolina, 28791

United States

ECU Health Oncology Kenansville

Kenansville, North Carolina, 28349

United States

ECU Health Oncology Kinston

Kinston, North Carolina, 28501

United States

ECU Health Oncology Richlands

Richlands, North Carolina, 28574

United States

UHHS-Chagrin Highlands Medical Center

Beachwood, Ohio, 44122

United States

Miami Valley Hospital South

Centerville, Ohio, 45459

United States

Geauga Hospital

Chardon, Ohio, 44024

United States

University of Cincinnati Cancer Center-UC Medical Center

Cincinnati, Ohio, 45219

United States

Good Samaritan Hospital - Cincinnati

Cincinnati, Ohio, 45220

United States

Bethesda North Hospital

Cincinnati, Ohio, 45242

United States

TriHealth Cancer Institute-Westside

Cincinnati, Ohio, 45247

United States

TriHealth Cancer Institute-Anderson

Cincinnati, Ohio, 45255

United States

Case Western Reserve University

Cleveland, Ohio, 44106

United States

Ohio State University Comprehensive Cancer Center

Columbus, Ohio, 43210

United States

Columbus Oncology and Hematology Associates Inc

Columbus, Ohio, 43214

United States

Riverside Methodist Hospital

Columbus, Ohio, 43214

United States

Grant Medical Center

Columbus, Ohio, 43215

United States

Doctors Hospital

Columbus, Ohio, 43228

United States

Miami Valley Hospital

Dayton, Ohio, 45409

United States

Premier Blood and Cancer Center

Dayton, Ohio, 45409

United States

Miami Valley Hospital North

Dayton, Ohio, 45415

United States

Delaware Health Center-Grady Cancer Center

Delaware, Ohio, 43015

United States

Grady Memorial Hospital

Delaware, Ohio, 43015

United States

Columbus Oncology and Hematology Associates

Dublin, Ohio, 43016

United States

Dublin Methodist Hospital

Dublin, Ohio, 43016

United States

Atrium Medical Center-Middletown Regional Hospital

Franklin, Ohio, 45005-1066

United States

Miami Valley Cancer Care and Infusion

Greenville, Ohio, 45331

United States

OhioHealth Mansfield Hospital

Mansfield, Ohio, 44903

United States

OhioHealth Marion General Hospital

Marion, Ohio, 43302

United States

UH Seidman Cancer Center at Lake Health Mentor Campus

Mentor, Ohio, 44060

United States

UH Seidman Cancer Center at Southwest General Hospital

Middleburg Heights, Ohio, 44130

United States

University Hospitals Parma Medical Center

Parma, Ohio, 44129

United States

Mercy Health - Perrysburg Hospital

Perrysburg, Ohio, 43551

United States

University Hospitals Portage Medical Center

Ravenna, Ohio, 44266

United States

UH Seidman Cancer Center at Firelands Regional Medical Center

Sandusky, Ohio, 44870

United States

Mercy Health - Saint Anne Hospital

Toledo, Ohio, 43623

United States

Toledo Clinic Cancer Centers-Toledo

Toledo, Ohio, 43623

United States

Upper Valley Medical Center

Troy, Ohio, 45373

United States

University Hospitals Sharon Health Center

Wadsworth, Ohio, 44281

United States

University of Cincinnati Cancer Center-West Chester

West Chester, Ohio, 45069

United States

UH Seidman Cancer Center at Saint John Medical Center

Westlake, Ohio, 44145

United States

University of Oklahoma Health Sciences Center

Oklahoma City, Oklahoma, 73104

United States

Mercy Hospital Oklahoma City

Oklahoma City, Oklahoma, 73120

United States

Saint Alphonsus Cancer Care Center-Baker City

Baker City, Oregon, 97814

United States

Saint Charles Health System

Bend, Oregon, 97701

United States

Clackamas Radiation Oncology Center

Clackamas, Oregon, 97015

United States

Providence Cancer Institute Clackamas Clinic

Clackamas, Oregon, 97015

United States

Bay Area Hospital

Coos Bay, Oregon, 97420

United States

Providence Newberg Medical Center

Newberg, Oregon, 97132

United States

Saint Alphonsus Cancer Care Center-Ontario

Ontario, Oregon, 97914

United States

Providence Willamette Falls Medical Center

Oregon City, Oregon, 97045

United States

Providence Portland Medical Center

Portland, Oregon, 97213

United States

Providence Saint Vincent Medical Center

Portland, Oregon, 97225

United States

Saint Charles Health System-Redmond

Redmond, Oregon, 97756

United States

Lehigh Valley Hospital-Cedar Crest

Allentown, Pennsylvania, 18103

United States

Saint Luke's Cancer Center - Allentown

Allentown, Pennsylvania, 18104

United States

Saint Luke's University Hospital-Bethlehem Campus

Bethlehem, Pennsylvania, 18015

United States

Lehigh Valley Hospital - Muhlenberg

Bethlehem, Pennsylvania, 18017

United States

Pocono Medical Center

East Stroudsburg, Pennsylvania, 18301

United States

Saint Luke's Hospital-Anderson Campus

Easton, Pennsylvania, 18045

United States

Lehigh Valley Hospital-Hazleton

Hazleton, Pennsylvania, 18201

United States

Pennsylvania Hospital

Philadelphia, Pennsylvania, 19107

United States

Thomas Jefferson University Hospital

Philadelphia, Pennsylvania, 19107

United States

UPMC-Magee Womens Hospital

Pittsburgh, Pennsylvania, 15213

United States

University of Pittsburgh Cancer Institute (UPCI)

Pittsburgh, Pennsylvania, 15232

United States

Saint Luke's Hospital-Quakertown Campus

Quakertown, Pennsylvania, 18951

United States

Saint Joseph Regional Cancer Center

Bryan, Texas, 77802

United States

Parkland Memorial Hospital

Dallas, Texas, 75235

United States

UT Southwestern/Simmons Cancer Center-Dallas

Dallas, Texas, 75390

United States

UT Southwestern/Simmons Cancer Center-Fort Worth

Fort Worth, Texas, 76104

United States

Memorial Hermann Texas Medical Center

Houston, Texas, 77030

United States

Memorial Hermann Northeast Hospital

Humble, Texas, 77338

United States

Memorial Hermann The Woodlands Hospital

The Woodlands, Texas, 77380

United States

Huntsman Cancer Institute/University of Utah

Salt Lake City, Utah, 84112

United States

Central Vermont Medical Center/National Life Cancer Treatment

Berlin Corners, Vermont, 05602

United States

University of Vermont Medical Center

Burlington, Vermont, 05401

United States

University of Vermont and State Agricultural College

Burlington, Vermont, 05405

United States

Inova Schar Cancer Institute

Fairfax, Virginia, 22031

United States

Inova Fair Oaks Hospital

Fairfax, Virginia, 22033

United States

Bon Secours Saint Francis Medical Center

Midlothian, Virginia, 23114

United States

Bon Secours Cancer Institute at Reynolds Crossing

Richmond, Virginia, 23230

United States

Providence Regional Cancer System-Aberdeen

Aberdeen, Washington, 98520

United States

PeaceHealth Saint Joseph Medical Center

Bellingham, Washington, 98225

United States

Highline Medical Center-Main Campus

Burien, Washington, 98166

United States

Providence Regional Cancer System-Centralia

Centralia, Washington, 98531

United States

Swedish Cancer Institute-Edmonds

Edmonds, Washington, 98026

United States

Saint Elizabeth Hospital

Enumclaw, Washington, 98022

United States

Providence Regional Cancer Partnership

Everett, Washington, 98201

United States

Saint Francis Hospital

Federal Way, Washington, 98003

United States

Swedish Cancer Institute-Issaquah

Issaquah, Washington, 98029

United States

Kadlec Clinic Hematology and Oncology

Kennewick, Washington, 99336

United States

Providence Regional Cancer System-Lacey

Lacey, Washington, 98503

United States

Saint Clare Hospital

Lakewood, Washington, 98499

United States

PeaceHealth Saint John Medical Center

Longview, Washington, 98632

United States

Harrison HealthPartners Hematology and Oncology-Poulsbo

Poulsbo, Washington, 98370

United States

Pacific Gynecology Specialists

Seattle, Washington, 98104

United States

Swedish Medical Center-Ballard Campus

Seattle, Washington, 98107

United States

Swedish Medical Center-Cherry Hill

Seattle, Washington, 98122-5711

United States

Swedish Medical Center-First Hill

Seattle, Washington, 98122

United States

PeaceHealth United General Medical Center

Sedro-Woolley, Washington, 98284

United States

Providence Regional Cancer System-Shelton

Shelton, Washington, 98584

United States

Saint Michael Cancer Center

Silverdale, Washington, 98383

United States

Franciscan Research Center-Northwest Medical Plaza

Tacoma, Washington, 98405

United States

Northwest Medical Specialties PLLC

Tacoma, Washington, 98405

United States

PeaceHealth Southwest Medical Center

Vancouver, Washington, 98664

United States

Providence Saint Mary Regional Cancer Center

Walla Walla, Washington, 99362

United States

Providence Regional Cancer System-Yelm

Yelm, Washington, 98597

United States

Aurora Cancer Care-Southern Lakes VLCC

Burlington, Wisconsin, 53105

United States

Aurora Saint Luke's South Shore

Cudahy, Wisconsin, 53110

United States

Aurora Health Care Germantown Health Center

Germantown, Wisconsin, 53022

United States

Aurora Cancer Care-Grafton

Grafton, Wisconsin, 53024

United States

Aurora BayCare Medical Center

Green Bay, Wisconsin, 54311

United States

Aurora Cancer Care-Kenosha South

Kenosha, Wisconsin, 53142

United States

Aurora Bay Area Medical Group-Marinette

Marinette, Wisconsin, 54143

United States

Aurora Cancer Care-Milwaukee

Milwaukee, Wisconsin, 53209

United States

Aurora Saint Luke's Medical Center

Milwaukee, Wisconsin, 53215

United States

Medical College of Wisconsin

Milwaukee, Wisconsin, 53226

United States

Aurora Sinai Medical Center

Milwaukee, Wisconsin, 53233

United States

ProHealth D N Greenwald Center

Mukwonago, Wisconsin, 53149

United States

Cancer Center of Western Wisconsin

New Richmond, Wisconsin, 54017

United States

ProHealth Oconomowoc Memorial Hospital

Oconomowoc, Wisconsin, 53066

United States

Vince Lombardi Cancer Clinic - Oshkosh

Oshkosh, Wisconsin, 54904

United States

Aurora Cancer Care-Racine

Racine, Wisconsin, 53406

United States

Vince Lombardi Cancer Clinic-Sheboygan

Sheboygan, Wisconsin, 53081

United States

Aurora Medical Center in Summit

Summit, Wisconsin, 53066

United States

Vince Lombardi Cancer Clinic-Two Rivers

Two Rivers, Wisconsin, 54241

United States

UW Cancer Center at ProHealth Care

Waukesha, Wisconsin, 53188

United States

Aurora Cancer Care-Milwaukee West

Wauwatosa, Wisconsin, 53226

United States

Aurora West Allis Medical Center

West Allis, Wisconsin, 53227

United States

Billings Clinic-Cody

Cody, Wyoming, 82414

United States

Welch Cancer Center

Sheridan, Wyoming, 82801

United States

Collaborators and Investigators

Sponsor: Alliance for Clinical Trials in Oncology

Priscilla Brastianos, MD, STUDY_CHAIR, Massachusetts General Hospital

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2019-10-17

Study Completion Date2028-06

Study Record Updates

Study Start Date2019-10-17

Study Completion Date2028-06

Terms related to this study

Additional Relevant MeSH Terms

CDK Gene Mutation
Metastatic Malignant Neoplasm in the Brain
Metastatic Malignant Solid Neoplasm
NTRK Family Gene Mutation
PI3K Gene Mutation
ROS1 Gene Mutation
KRAS G12C Mutation